Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • CIN2
  • AIS
  • Cervical Cancer
  • VIN 1
  • CIN 3
  • VIN 2
  • CIN1
  • VIN 3
  • Genital Wart
  • HPV Infections
  • Vulvar Cancer
  • Vaginal Cancer
  • VaIN1
  • VaIN2
  • VaIN3
Type
Interventional
Phase
Phase 3
Design
Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Prevention

Participation Requirements

Age
Between 9 years and 45 years
Gender
Only males

Description

This study (protocol 9-HPV-3003) is an immunogenicity and safety study in the subjects (9-19 years of age) who received the 9-valent HPV recombinant vaccine compared with the subjects (20-45 years of age). In this study, we will assess whether the immunogenicity of the 9-valent HPV vaccine given 3-d...

This study (protocol 9-HPV-3003) is an immunogenicity and safety study in the subjects (9-19 years of age) who received the 9-valent HPV recombinant vaccine compared with the subjects (20-45 years of age). In this study, we will assess whether the immunogenicity of the 9-valent HPV vaccine given 3-dose schedule in the subjects (9-19 years of age) in noninferior to that in the subjects (20-45 years of age) receiving 3 doses, while assessing the safety of this vaccine.

Tracking Information

NCT #
NCT04895020
Collaborators
Chongqing Bovax Biopharmaceutical Co., Ltd.
Investigators
Study Director: Person(s) responsible for the overall scientific leadership of Lv Zhejiang Provincial Center for Disease Control and Prevention